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Abstract
Background: Arsenic (As) exposure is a significant worldwide environmental health concern. Chronic exposure via
contaminated drinking water has been associated with an increased incidence of a number of diseases, including
reproductive and developmental effects. The goal of this study was to identify adverse outcomes in a mouse model of early
life exposure to low-dose drinking water As (10 ppb, current U.S. EPA Maximum Contaminant Level).
Methodology and Findings: C57B6/J pups were exposed to 10 ppb As, via the dam in her drinking water, either in utero
and/or during the postnatal period. Birth outcomes, the growth of the F1 offspring, and health of the dams were assessed
by a variety of measurements. Birth outcomes including litter weight, number of pups, and gestational length were
unaffected. However, exposure during the in utero and postnatal period resulted in significant growth deficits in the
offspring after birth, which was principally a result of decreased nutrients in the dam’s breast milk. Cross-fostering of the
pups reversed the growth deficit. Arsenic exposed dams displayed altered liver and breast milk triglyceride levels and serum
profiles during pregnancy and lactation. The growth deficits in the F1 offspring resolved following separation from the dam
and cessation of exposure in male mice, but did not resolve in female mice up to six weeks of age.
Conclusions/Significance: Exposure to As at the current U.S. drinking water standard during critical windows of
development induces a number of adverse health outcomes for both the dam and offspring. Such effects may contribute to
the increased disease risks observed in human populations.
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Introduction
Chronic exposure to arsenic (As), by contamination of drinking
water from natural geological sources, is a significant worldwide
environmental health concern [1,2]. As many as 25 million people
in the United States are exposed to As at levels above the current
EPA standard from private, unregulated wells, and worldwide the
estimated exposure is several hundreds of millions of people.
Chronic exposure to such elevated levels has been associated with
a variety of adverse health impacts in human epidemiology studies,
including various cancers, cardiovascular disease, diabetes and
developmental/reproductive effects [2,3,4]. The mechanism(s) by
which arsenic can induce or contribute to such a wide array of
adverse health impacts, over a wide range of exposures, have yet to
be elucidated.
Exposure events during critical windows of fetal and postnatal
(PN) development pose a serious risk for adverse health outcomes
later in life [5]. An increasing number of animal and human
epidemiological studies have indicated an association between As
exposure and adverse reproductive and developmental outcomes.
Arsenic readily crosses the placenta [6,7], but it has been shown
that As transfer via the breast milk is limited [8]. Prenatal exposure
to high levels of As (ppm range) in mouse models has been
reported to result in a variety of adverse effects including placental
dysplasia and loss of fecundity [9], transplacental carcinogenicity
[10], early onset of atherosclerosis [11], and neural tube defects
[12]. Prenatal exposure of mice to lower doses of As (50 ppb) has
been shown to result in learning deficits [13] and alterations in
lung structure and function [14].
Epidemiology studies have shown that exposure to As during
gestation is associated with a number of adverse effects on the
fetus, including low birth weight, survival, and spontaneous
abortion [15,16,17,18,19]. However, most of this work has been
conducted in areas with relatively high exposures (several hundred
ppb), such as Bangladesh and Taiwan. A number of studies have
identified adverse immunological outcomes following early life As
exposure, including decreased infant thymic development, de-
creased immune factors in breast milk, increased acute respiratory
infections in offspring, and the activation of inflammation in the
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placenta and cord blood [20,21,22,23]. Early life As exposure has
also been associated with an increased incidence of cancer and
bronchiectasis in adulthood, even several decades after cessation of
exposure [24]. Interestingly, in Bangladesh, no effects have been
observed on infant development at 7 or 18 months [25,26].
Based on cancer evidence, the U.S. EPA’s current Maximum
Contaminant Level (MCL) for As in public drinking water supplies
is 10 ppb (0.13 mM) [27], which was recently revised from 50 ppb.
Since that regulatory change, a number of studies have reported
significant effects of As exposure at or below 10 ppb in
experimental model systems [14,28,29,30]. The effects of low
dose As at the current EPA standard on susceptible populations,
such as pregnant women and infants, have been largely
unexplored. Our goal was to develop a mouse model of early
life As exposure through which we could identify critical windows
of exposure that might result in adverse impacts on the
development of the immune system later in life. However,
following the development of our model, we unexpectedly
observed that gestational and post natal As exposure at 10 ppb
caused immediate effects on the rate of body weight gain of the F1
offspring. Thus, the studies presented here were designed to
further explore the developmental outcomes following low dose As
exposure during gestation and lactation.
Results
Birth outcomes
The experimental model of exposure is detailed in Figure 1 and
the Methods section. Differences were not observed in any birth
outcome (n = 14–17 dams per exposure), such as litter size (control:
7.5 (60.3) pups; arsenic: 7.4 (60.3) pups), gestational length
(control: 20.2 (60.33) days; arsenic: 19.6 (60.38) days), the
average weight of the litter or the survival of the pups (control:
1.28 (60.01) grams; arsenic: 1.26 (60.02) grams).
Growth of F1 offspring
Following birth, pups were monitored daily to assess survival
and development. Survival and developmental milestones (eye
opening, pinna unfolding, appearance of fur) was not differentially
affected by the As exposure paradigm. As early as day 10 post
natal, offspring exposed to As displayed significant decreases in
growth (evidenced by total body weight), regardless of the timing
of As exposure (Figure 2A). At the time of weaning (day 21 post
natal) many of the As-exposed offspring were so small that it was
not feasible to separate the offspring from the dams at the day of
weaning. All pups were maintained with the dam until they
reached a weight standard for separation of 7 grams. At weaning,
mean weight values for IU, PN and IU&PN As exposed offspring
were 7.5, 7.6 and 7.1 grams, respectively. The mean control
weight was 9.2 grams. Given this cutoff for separation from the
dam, percentages of mice requiring a delayed wean for control,
IU, PN and IU&PN exposures were as follows: 0%, 33%, 25%
and 46%, respectively. This growth deficit persisted through day
28 PN, regardless of whether or not a delayed wean was required.
At day 42 PN, the growth deficit was still apparent in female but
not in male mice (Figure 2B). Prior to this time point, both genders
of mice were equally affected (Figure S1).
Arsenic tissue concentrations
To assess the direct exposure of the F1 offspring to As, total As
levels in the placenta, dam’s breast milk, pup stomach content (day
10 and 21 PN), and urine were measured by ICP-MS across all
exposure groups at various time points pre-, during and post-
pregnancy. Arsenic levels in the placentas, dam’s milk and pup
stomachs were near the limits of detection in all exposure groups.
There was no observable increase in the As concentrations in the
placenta or milk, but there was a significant increase in the
stomach As contents of the pups that received As exposure IU and
Figure 1. Experimental model of developmental arsenic exposure in C57BL/6 mice. Following the detection of cervical plugs, mated
females were exposed to control water or 10 ppb As in drinking water through the gestational period. At the birth of their pups, dams in each
exposure group were further divided into sub-groups receiving control water or 10 ppb As in drinking water through 30 days of age (n = 14–17 dams
per exposure). Weaning from the dam took place at day 21 PN (or later if a pup did not reach the 7 gram weight cut-off). This resulted in 4 overall
exposure groups: 1. Control (no As drinking water exposure; 2. Postnatal (PN, offspring receiving 10 ppb As from PN days 1–30); 3. In utero (IU,
offspring receiving 10 ppb As from gestational day 1 through birth); 4. In utero & postnatal (IU&PN, offspring receiving 10 ppb As from gestational
day 1 through day 30 PN) At day 30 PN, all offspring were placed on control drinking water and growth was assessed until 6 weeks PN.
doi:10.1371/journal.pone.0038249.g001
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IU&PN compared to control offspring. This increase in stomach
As levels was observed at day 10 PN, during which time the
offspring would be primarily consuming breast milk, as opposed to
drinking from the water bottle source of As. By day 21 PN, no
differences in As levels were detected in the stomach contents of
the pups. As expected, urinary excretion of As significantly
increased in the As exposure groups. Interestingly, while all mice
in the exposure groups received the same level of As (10 ppb),
excretion values decreased in the pregnant and lactating As-
exposed mice, when compared to As-exposed virgin mice. Mice
that were exposed to As only IU no longer excreted significant
levels of As during the postpartum period. Urinary As excretion
was primarily in the form of dimethylarsenate (DMA). Values are
represented in Table 1. Intake of water and excretion of urine
displayed a trending, but not significant, increase across the
exposure groups (Table S1).
Alterations in breast milk nutrition
Given that the growth deficit manifested during the postnatal
period (as early as day 10) and there was not a significant increase
in the exposure of the pups to As via the breast milk, we
hypothesized that other alterations in the dam’s milk were at least
partially responsible. Obvious differences in the rearing of the pups
by the dams in different exposure groups were not observed. By
day 1 PN, all pups displayed prominent milk spots and by day 10
PN, no significant difference was observed in the weight of the
stomach contents of the pups, which confirmed that the offspring
in all exposure groups were being fed and general milk production
was intact. The milk of the dams in all exposure groups was
assessed for total protein and triglyceride (TG) concentrations.
Protein concentrations were not significantly different (Figure 3A),
but TG concentrations displayed a significant decrease in all As
exposure groups compared to control (Figure 3B). No differences
were observed in the amount of milk collected in the different
exposure groups.
Triglyceride levels in the dams
We were interested to assess how exposure to As might alter
lipid metabolism in the dams during the course of pregnancy and
lactation. Unexpectedly, we found a significant increase in the
incidence of liver steatosis in the As-exposed dams at day 15.5
gestation. None of the control dams displayed gross liver steatosis
at day 15.5 gestation, while 55.5% (5/9) of the As exposure dams
displayed gross liver steatosis (* p,0.05, compared to control,
Fisher’s exact probability test). Liver steatosis was confirmed at the
histological level (Figure 4 A–F). Maternal weight gain was not
altered by As exposure (Figure S2). Gross liver steatosis was not
observed at day 21 PN in any of the exposure groups, indicating
that the effects are transient. The total TG levels in the serum and
livers of pregnant (gestational day 15.5) and lactating mice (PN day
15–18) were also measured (Table 2). Significant decreases were
observed in the levels of total serum TG during pregnancy and
lactation for mice receiving As in all exposure paradigms. Liver
TG were significantly increased in mice exposed to As during
gestation, as expected, given the gross liver steatosis. However,
liver TG levels displayed a trending, but not significant, increase in
As exposure groups during the lactation period.
Profiling of serum lipoproteins using Fast Protein Liquid
Chromatography revealed no clear differences between the
control and As-exposed dams for cholesterol levels in the
lipoprotein fractions, indicating that 10 ppb As does not substan-
tially affect the number of lipoprotein particles for any of the
fractions (Figure 5). Interestingly, the distribution of TG over the
fractions was markedly affected. The very low density lipoprotein
(VLDL) fractions of the As-treated mice contained more TG and
its distribution was shifted to larger VLDL particles. The low,
intermediate, and high density lipoprotein fractions (LDL, IDL,
and HDL, respectively), all showed a decreased TG level for the
As-treated dams. In accordance with the results from Table 2, the
area under the curve for TG was smaller for the As-treated mice
(Figure 5).
Cross-fostering of F1 offspring
To assess the level to which decreased milk nutrients
contributed to the growth deficit, we designed a series of cross-
fostering experiments. In these experiments, offspring from
Figure 2. Effects of in utero and postnatal arsenic exposure on
growth of offspring. (A). The weight (grams) of offspring was
monitored over the course of development and is shown across all four
exposure groups at birth, day 10, 21, and day 28 PN. Male and female
mice are included. Birth, n = 21–25; Day 10, n = 17–21; Day 21, n = 65–71;
Day 28, n = 44–52. One Way ANOVA, compared to control for each
respective time point (B.) Mouse weights separated by gender at day 42
PN across all four exposure groups; n = 49–54. Male mice in all exposure
groups are represented with open shapes and female mice with closed
shapes. One Way ANOVA for female mice, compared to unexposed
female mice. Asterisks indicate statistical significance, * p,0.05, **
p,0.01*** p,0.001, ****p,0.0001. Error bars represent mean 6 SEM.
doi:10.1371/journal.pone.0038249.g002
Developmental Arsenic Exposure
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opposing gestational exposure groups (control or gestational As)
were exchanged and fostered. We observed that we could reverse
the growth phenotype by simply exchanging the litters and dams
from opposing exposure groups (Figure 6, Column C and D).
Fostering within the exposure group recapitulated the original
phenotype (Figure 6, Column E and F).
Discussion
In the conduct of an experiment designed to examine immune
effects later in life from in utero exposure to As at the current U.S.
EPA drinking water standard, we were surprised to observe
significant short-term effects of these exposures on the F1 offspring
and the dams. Specific effects included decreased growth of the F1
offspring and altered TG levels and profiles in the dams. Decreases
in the nutrient content of the dam’s breast milk, specifically TGs,
appear to play a role in the growth deficits observed in the F1
offspring. The growth deficit was reversed by cross-fostering of the
pups.
Arsenic concentrations were measured in the dam’s milk, pup
stomachs, placentas, and dam’s urine, which confirmed that As
was not transferred via the breast milk. In two exposure groups (IU
and PN), we observed a trend towards decreased As levels in the
milk, which was also recently reported in a similar mouse study
with much higher doses of exposure [31]. These results are
consistent with published reports of healthy lactating women
exposed to As [8]. We did not detect significant increases in the
levels of As in the placentas of the exposed mice compared to
control mice. It is possible that As transfers through the placenta at
a greater level in the exposed mice, but the low level of As used in
this model and the detection limits of the ICP-MS impair our
ability to measure it. Arsenic has been shown to transfer through
Table 1. Arsenic measurementsa in tissue samples from dams and pups.
Control As (2 week)
Virgin Mice
Urine (ug/L) 11.91 (5.0) 56.01 (13.1)***
Control IU
Gestational Day 15.5
Placenta (ng/g) 1.20 (0.4) 1.00 (0.5)
Dam’s Urine (ug/L) 6.89 (2.5) 26.75 (6.9)*##
Control IU PN IU & PN
PN day 10–12
Pup stomach (ng/g) 0.64 (0.3) 2.1 (0.5) ** 1.17 (0.4) 2.69 (1.0) ***
Dam’s Milk (ng/g) 1.56 (0.6) 0.89 (0.4) 0.78 (0.5) 1.73 (1.0)
Dam’s Urine (ug/L) 4.41 (2.5) 5.94 (3.3) 19.68 (3.1)***### 20.00 (1.3)***###
PN day 21
Pup stomach (ng/g) 4.8 (0.4) 5.0 (0.3) 4.6 (0.9) 3.7 (0.8)
aTotal As levels were measured by ICP-MS, as described in Methods (n = 3–6). Values represent mean 6 SEM. Asterisks indicate statistical significance from respective
control group in matching row.
*p,0.05,
**p,0.01,
***p,0.001. Number sign indicates statistical significance from virgin female mouse exposed to 10 ppb As for 2 weeks. One Way ANOVA.
doi:10.1371/journal.pone.0038249.t001
Figure 3. Effects of arsenic exposure on nutritional composition of dam’s breast milk. Breast milk was collected between day 10–12 PN.
Breast milk was analyzed for (A.) total protein concentrations and (B.) total TG concentrations. Asterisks indicate statistical significance, ** p,0.01, ***
p,0.001, One Way ANOVA compared to control. Error bars equal mean 6 SEM (n = 8–9 mice per exposure).
doi:10.1371/journal.pone.0038249.g003
Developmental Arsenic Exposure
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the placenta in human models of exposure and in mouse models
with higher levels of exposure [6,7,32]. Given the dramatic effect
on growth in the offspring, we were concerned that the pups may
be acquiring exposure to As from another external source, such as
the dam’s urine. To assess such exposure, we also measured the
stomach content of the pups. While we did not see a significant
increase in the As levels in the milk, we did see a significant
increase in the As levels the pup stomachs in two exposure groups:
Figure 4. Effects of gestational arsenic exposure on liver steatosis and gross organ changes in the dam. Dams were sacrificed at
gestation day 15.5. (A, B.) Detection of liver steatosis at the gross level was observed in a significant percentage of the As exposed mice (C–F.)
Histological hematoxylin and eosin staining in (C.,E.) control and (D., F.) As-exposed dams. Scale bars indicate magnification.
doi:10.1371/journal.pone.0038249.g004
Table 2. Exposure to Arsenic during gestation and lactation affect total TG levels in the serum and liver.
Control IU
Gestational Day 15.5
Serum TG (mg/dL) 119 (8.5) 74 (0.5)**
Liver TG (mg/dL/mg liver) 4.1 (0.1) 6.85 (0.7)*
Control IU PN IU & PN
PN day 15–18
Serum TG (mg/dL) 110 (10.3) 70 (4.0)* 71 (9.9)* 65 (5.7)*
Liver TG (mg/dL/mg liver) 4.2 (0.6) 6.1 (1.4) 5.3 (0.7) 5.44 (0.4)
Asterisks indicate statistical significance,
*p,0.05 and
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IU and IU&PN at day 10 PN. However, it is unlikely that these
elevated levels are a result of external exposure, via the urine or
some other source, given that we did not observe such increases in
the PN group. The dams in the PN exposure group excreted a
significantly higher level of As in the urine compared to the IU
group during the postnatal period. Thus, the basis for this increase
in stomach As in these two groups is unclear. The overall levels of
As in the stomachs at day 21 were increased compared to day 10
PN. This was likely a result of the pup’s consumption of chow at
this time point.
Interestingly, we also observed significant decreases in As
excretion by the dams in all As exposure groups during the
gestational and postnatal period, compared to virgin mice
ingesting the same level of As. There was a trend towards
increased water consumption and urine output in the As-exposed
mice during pregnancy (and across all groups during the
lactational period), but given the magnitude of these trends, the
changes in water consumption and urine output are unlikely to
account entirely for the significant decrease in urinary As output.
Recent epidemiological data has shown that pregnancy can
significantly alter the metabolism of As [33], but one challenge in
the field has been extrapolating animal model studies of As
exposure to human studies because mice are very efficient at
metabolizing As [34]. Further research in this area is needed, but
these data suggest that urinary As levels in pregnant mice may not
be an accurate marker of the level of drinking water exposure.
The impeded growth of As-exposed offspring observed in this
study was unexpected, given the low dose (10 ppb) of As used.
Similar growth deficits have been observed in a high dose [10, 50
and 100 mg/L] IU exposure model of rats [35]. Other studies
have used similar models of exposure (ppb and ppm levels of As
during gestation and lactation), but have not reported changes in
body weight gain early in life [10,14,32]. It has become clear in
comparing different experiments that the dose of As is very
important, as well as understanding and controlling the back-
ground concentrations of As in the diet and bedding [36].
Moreover, arsenic has been shown to display complicated, multi-
phasic dose response curves over a broad range that suggest
different physiological effects at different dose ranges [37], so in
retrospect it is not surprising to observe a different effect at these
lower exposures, which might then be superseded by other effects
at higher doses. We also recognize that many of these effects
appear to be transient and can be experimentally ameliorated,
suggesting that differences in the timing of exposure and in the
experiment endpoints between this study and other studies using
similar models could influence the observed results. It is also
interesting that we did not observe greater effects in the groups
with the combined exposure period (i.e., IU+PN) versus groups
with only one or the other period of exposure (IU or PN). We
cannot rule out the possibility that there is some capability to adapt
to such low level exposures. Clearly, the response curves of As
exposure, particularly at low levels, are complex, but these
unexpected low-level effects on fetal growth warrant further
investigation.
Based on our results, it is clear that As effects on the dam play a
major role in the growth deficit of the offspring. The results of the
fostering experiments suggest that the milk is the major
contributor to the effects we have observed. However, we cannot
definitively rule out that small behavioral changes in the dams
Figure 5. Effects of arsenic exposure on the distribution of
cholesterol and triglycerides over serum lipoprotein fractions.
Dams were fasted for 6 hours on PN day 21 and pooled serum of 4 As
(IU&PN) treated dams (open triangles) and 3 controls (black circles) was
used for lipoprotein profiling by FPLC. Fractions were assayed for TG
(top panel) and total cholesterol levels (bottom panel).
doi:10.1371/journal.pone.0038249.g005
Figure 6. Effects of cross-fostering on postnatal growth of in
utero arsenic-exposed pups. The average litter weight (grams) of
offspring at weaning (day 21 PN) was assessed following fostering.
Immediately following birth, all dams were placed on control drinking
water through the weaning period. Groups were as follows: (A.) Control
offspring remaining with biological mom through weaning/not
fostered (n = 11 litters); (B.) 10 ppb IU As exposed mice remaining with
biological mom/not fostered (n = 11 litters); (C.) Control offspring
fostered by 10 ppb IU As mom (n = 5 litters); (D.) 10 ppb IU As
offspring fostered by control mom (n = 5 litters); (E.) Control offspring
fostered by a non-biological control mom (n = 3 litters); (F.) 10 ppb IU
As offspring fostered by a non-biological 10 ppb IU As mom (n = 3
litters). Asterisks indicate statistical significance, * p,0.05, ****
p,0.0001, One Way ANOVA compared to control mice remaining with
biological mom (column A). Error bars represent mean 6 SEM.
doi:10.1371/journal.pone.0038249.g006
Developmental Arsenic Exposure
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rearing of the pups did not play a role in the growth deficit.
Breastfeeding of infants in human populations with As exposure
has been shown to be protective against increased As exposure to
the infant [38]. Our results suggest that As exposure can impact
the composition and quality of breast milk, even when As is not
being directly transferred via the breastmilk. We also observed an
interesting gender-specific effect. These results suggest that female
mice are more vulnerable to early life As exposure, compared to
their male siblings, implying a hormonal contribution. Arsenic is a
well-documented endocrine disruptor and this could represent yet
another example of such actions in vivo [37,39,40,41].
We have previously reported that a combined exposure of adult
mice to As followed by a sublethal infection with influenza
significantly increased the severity of respiratory infection [42].
Based on our previous studies, we have hypothesized that exposure
to low levels of As may act as a predisposing factor, in which a
secondary stress is needed to induce the adverse health effects we
have observed. In the results reported in this study, we believe that
pregnancy/lactation can act as such a secondary stress in the
dams. Under conditions of physiological stress, such as during
pregnancy and lactation, small alterations in lipid metabolism may
be exacerbated, leading to the measureable decreases in the TG
concentration of the breast milk, altered lipid profliles and the liver
steatosis we observed in this study. The shift to increased VLDL
size in As-treated dams, as indicated by FPLC analysis, may reflect
an increase in hepatic de novo lipogenesis [43], which would be in
agreement with the fatty livers observed in a significant number of
the As-exposed dams. Alternatively, As exposure may result in
impaired VLDL-TG catabolism, but this would be expected to
result in elevated serum TG levels. It is conceivable that As affects
serum lipid metabolism via multiple mechanisms with lower TG
levels as the ultimate effect. An elevated serum TG by increased
production or decreased catabolism of VLDL-TG may for
instance be compensated by increased hepatic clearance of IDL/
LDL triglycerides, which would be supported by the lower TG
levels in the corresponding fractions from the As-exposed dams.
Regardless, the lower serum TG levels would potentially reduce
availability of lipids in peripheral tissues, including mammary
glands. Acute fatty liver of pregnancy (AFLP) is a specific clinical
disease reported in a small percentage of human pregnancies [44].
It is interesting to speculate that such a background of altered lipid
metabolism, itself elaborated by the physiological stress of
pregnancy, may be further altered by As.
Overall, this study indicates that low-level As exposure during
the IU or PN period results in a number of immediate adverse
effects, including altered TG levels and profiles and growth deficits
in the F1 offspring. Many of these outcomes were direct effects on
the dam, which manifested as adverse outcomes in the F1
offspring. The results suggest that exposure of vulnerable
populations to As, perhaps at levels as low as the current MCL
of 10 ppb, may induce a significant increase in adverse health
outcomes, which has been previously unrecognized. It is well
documented that exposure to chemicals and environmental
toxicants during the developmental period can have both
immediate and long-term health problems. The goal of our future
research will be to address the impact of early-life As exposure on
the development and relative adverse health risks of these F1
individuals as adults, and on their F2 offspring.
Methods
Animal husbandry
All animal studies were conducted in accordance with
Association for Assessment and Accreditation of Laboratory
Animal Care (AALAC)-approved guidelines using a protocol
approved by the Dartmouth Institutional Animal Care and Use
Committee (IACUC). Approval protocol number for Dartmouth
IACUC was 10-10-02. All animals were treated humanely and
with regard for alleviation of suffering. C57BL/6J mice (Jackson
Labs, Bar Harbor, ME) were housed in ventilated cages with AIN-
76A chow (Harlan Teklad, Madison, WI, ad lib) and corncob and
carefresh bedding (Scott’s Distributing, Hudson, NH). Background
As concentrations in the diet were less than 20 ppb, which is a
level too low to speciate. We have demonstrated in previous
studies that the bioavailable fraction of inorganic arsenic in this
diet is low and that we can clearly distinguish an experimental
signal as compared to control by exposing animals to drinking
water As at 10 ppb [36].
Mated mice were acclimated on the AIN-76A diet for 2 weeks
prior to mating. In this model, following the detection of cervical
plugs, naı̈ve pregnant mice were exposed to control or 10 ppb As
in drinking water through the gestational and weaning period.
Males were not exposed to As prior to mating. At birth, dams in
control and As exposure groups were further split into groups
receiving control or 10 ppb As in drinking water, which resulted in
4 overall exposure groups: 1. Control (no As drinking water
exposure); 2. Postnatal (PN, offspring receiving 10 ppb As from
PN days 1–30); 3. In utero (IU, offspring receiving 10 ppb As from
gestational day 1 through birth); 4. In utero & postnatal (IU&PN,
offspring receiving 10 ppb As from gestational day 1 through day
30 PN). (Figure 1). Starting at day 18 gestation, cages were
monitored twice daily for the birth of pups. Litters were not culled.
Litters were monitored for developmental milestones, such as eye
opening, pinna unfolding and the appearance of fur. Offspring
were weaned from the mothers at day 21 PN and continued with
their designated drinking water exposure through day 30 PN.
From days 30–42 PN, all offspring were maintained on deionized
distilled water ddH2O (no As). In all instances (dams and
offspring), mice not being exposed to As during specified time
frames, were given ddH2O. Background As levels in the ddH20
were below 1 ppb. Animals were euthanized with carbon dioxide.
Maternal necropsies were conducted at day 15.5 gestation or at
various time points during lactation. F1 offspring necropsies were
conducted at day 10, 21 and 42 PN. No gross lesions or visceral
internal malformations (observed by gross physical observation at
necropsy) were noted in the FI offspring at any time point up to
the termination of the study at day 42 postnatal. A subset of dams
and virgin mice from each exposure group (n = 3–6) was placed in
metabolic cages (Nalgene) for a period of 24 hours at indicated
time points to facilitate collection of urine and measurement of
drinking water intake (Table S1).
Cross-fostering of pups
Litters born to a control dam or a gestationally As-exposed dam
within 12 hours of each other were eligible for cross-fostering.
Fostering of litters always occurred within 12 hours of birth. All
biological offspring were removed, the litters were culled to seven
pups, and they were transferred, as a group, to the cage of the
foster dam. The behavior of the dam was monitored for one hour
post-fostering to ensure acceptance of the litter. All dams were
maintained on deionized distilled water ddH2O (no As) following
birth. Weight (grams) of fostered offspring was assessed at day 21
PN.
Arsenic exposure
Sodium arsenite (Sigma Aldrich, St. Louis, MO) was prepared
from stock solution in ddH2O to yield a 10 ppb (mg/L)
concentration of drinking water. The arsenic concentration in
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the final solution was confirmed by induction-coupled plasma
mass spectrometry (ICP-MS) metal analysis at Dartmouth’s Trace
Elements Analysis Core Facility. Drinking water was changed
twice weekly.
Offspring growth
At birth, the gestational length, number of pups, average litter
weight (weight of individual pups/number of pups in litter),
number of dead pups, and number of pups with malformations
were recorded. Weight (grams) was recorded for offspring at birth,
day 10, day 21, day 28 and day 42 PN.
Liver histology
Liver steatosis in the dams was observed at the gross
observational level. For histological confirmation, livers were
removed and fixed in formaldehyde, paraffin embedded, sliced
and stained with hematoxylin and eosin.
Collection of breast milk
Dams (day 10–12 postnatal) were separated from pups for
6 hours to allow for milk accumulation. Dams were lightly
anesthetized (i.p.) with 9:1 ketamine:xylazine mix at 0.1 ml/30 g
body weight and injected (i.p.) with 2 IU (100 uL) of oxytocin
(Sigma-Aldrich, St. Louis, MO). Dams were milked by gentle
manual stimulation of the teat and collection with a pipette. Milk
was stored at 220 degrees C.
Analysis of protein levels
Milk samples were diluted in PBS and assayed for protein (1:400
dilution). Protein concentrations were determined by BCA Protein
Assay (Pierce, Rockford, IL), according to manufacturer’s instruc-
tions.
Collection of serum and livers
Dams were fasted for 6 hours. Blood was collected from the
vena cava and livers were collected and snap frozen. Liver tissue
(,150 mg) was homogenized in PBS using the Bullet Blender
Homogenizer (Next Advance, Cambridge, MA).
Analysis of triglycerides
Triglyceride concentrations were determined in the dam’s
breast milk (1:160 dilution), liver tissue (1:20 dilution) and serum
(1:2 dilution) samples from pregnant and lactating dams across all
exposure groups, using Wako L-type triglyceride (Wako Diagnos-
tics, Richmond, VA), according to manufacturer’s instructions.
Lipoprotein profiling
Lipoproteins were separated using fast protein liquid chroma-
tography (FPLC). 0.2 mL of pooled mouse plasma was injected
onto a Superose 6B 10/30 column (GE Healthcare Life Sciences,
Piscataway, NJ) and eluted at a constant flow of 0.2 mL/minute
with phosphate buffered saline (pH 7.4). The effluent was collected
in 0.2 mL fractions and triglyceride and cholesterol levels were
determined for each fraction using L-type and Cholesterol E kits
from Wako Diagnostics (Richmond, VA).
ICP-MS metal analysis
Total concentrations of trace metals in the breast milk (n = 4–5),
pup stomachs (n = 6), maternal urine (n = 3) and placentas (n = 3)
were measured by ICP-MS. Placenta, stomach and milk samples
were digested with 0.3–0.5 ml optima HNO3 at 70uC followed by
addition of 0.05–0.1 ml of H2O2. The digested samples were then
diluted to 3 ml (stomach and milk) or 5 ml (placenta) final volume.
These samples were then analyzed by ICP-MS (7700x, Agilent,
Santa Clara, CA) using He as a collision gas for As determination.
Quality control included sample analysis duplicates and spikes.
Urine was diluted 10-fold with 1% optima HNO3 and analyzed
for As by ICP-MS as above.
Statistical analysis
Statistical analysis was performed with Graphpad Prism 5.0d for
Macintosh (GraphPad Software Inc., La Jolla, CA) using two
tailed student t-test, ANOVA (with Bonferroni post test) or Fisher’s
exact probability test, requiring p,0.05 for statistical significance.
Supporting Information
Figure S1 Effects of in utero and postnatal arsenic
exposure on the gender specific growth of offspring.
Mouse weights separated by gender at (A.) day 21 and (B.) day 28
across all four exposure groups. No significant differences are
observed when comparing male vs female mice within the same
exposure group. n = 24–32.
(TIFF)
Figure S2 Gestational As exposure does not affect
weight gain in dams. Maternal weight gain (n = 9) was not
affected by As exposure (solid lines). The growth of virgin female
mice was also not affected by As exposure (dotted lines). Error bars
represent mean 6 SEM.
(TIFF)
Table S1 Water consumption and urine output in
virgin, pregnant and lactating mice.
(DOCX)
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